ID   YUL-PR8
AC   CVCL_C8TR
DR   Wikidata; Q123033999
RX   PubMed=35820397;
CC   Selected for resistance to: ChEBI; CHEBI_195559; Poziotinib (HMB781-36B).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Asn771delinsPheHis (N771delinsFH); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C8TI ! YUL-0019
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 19-12-24; Version: 3
//
RX   PubMed=35820397; DOI=10.1016/j.ccell.2022.06.006; PMCID=PMC9667883;
RA   Elamin Y.Y., Robichaux J.P., Carter B.W., Altan M., Tran H.,
RA   Gibbons D.L., Heeke S., Fossella F.V., Lam V.K., Le X.-N., Negrao M.V.,
RA   Nilsson M.B., Patel A., Vijayan R.S.K., Cross J.B., Zhang J.-J.,
RA   Byers L.A., Lu C., Cascone T., Feng L., Luthra R., San Lucas F.A.,
RA   Mantha G., Routbort M.J., Blumenschein G.R. Jr., Tsao A.S., Heymach J.V.;
RT   "Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy,
RT   resistance mechanisms, and impact of insertion location on drug
RT   sensitivity.";
RL   Cancer Cell 40:754-767.e6(2022).
//